Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Janine Arts"'
Autor:
Merel Derksen, Vicky Mertens, Eline A. Visser, Janine Arts, Wilma Vree Egberts, Ger J. M. Pruijn
Publikováno v:
RNA Biology, Vol 19, Iss 1, Pp 305-312 (2022)
RNase MRP is a ribonucleoprotein complex involved in the endoribonucleolytic cleavage of different RNAs. Mutations in the RNA component of the RNP are the cause of cartilage hair hypoplasia. Patients with cartilage hair hypoplasia are characterized b
Externí odkaz:
https://doaj.org/article/1ef8102a5f35469ebbed264ceedfbd6a
Supplementary Figure 3 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c39af0f5f6ef41056a576d89450f96d8
https://doi.org/10.1158/1535-7163.22485984.v1
https://doi.org/10.1158/1535-7163.22485984.v1
Supplementary Figure 1 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::590e732df14ab6ca794df04087e54932
https://doi.org/10.1158/1535-7163.22485990.v1
https://doi.org/10.1158/1535-7163.22485990.v1
The development of small-molecule activators of p53 is currently focused on malignancies containing a wild-type p53 genotype, which is present in most leukemias. JNJ-26854165 is one such p53-activating agent, but its mechanism of action remains to be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64c38c288da0c6a7c7ea8744fbbc031e
https://doi.org/10.1158/1535-7163.c.6532173
https://doi.org/10.1158/1535-7163.c.6532173
Supplementary Tables 1-3 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28859012634d90afc54f3627a7f5396d
https://doi.org/10.1158/1535-7163.22485978
https://doi.org/10.1158/1535-7163.22485978
Autor:
Patrick Angibaud, Kristof van Emelen, Martin Page, Michel Janicot, Marc Du Jardin, Luc Andries, Ilse Goris, Willem Talloen, Kees Bol, Eugene Cox, Veronique Vreys, Ian Hickson, Ron Gilissen, Laurence Decrane, Bruno Roux, Isabelle Pilatte, Lut Janssen, Ann Belin, Wim Floren, Ann Marin, Peter King, Janine Arts
Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clinical activity in the treatment of hematologic malignancies, but their activity in solid tumor indications has been limited. Most HDAC inhibitors in clinical development only tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2434ea75f5b9b9c5f4fbdf2a8833ab91
https://doi.org/10.1158/1078-0432.c.6517927
https://doi.org/10.1158/1078-0432.c.6517927
Supplementary Figure 2 from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eaaf8111b1b182909e833cad13f92fe
https://doi.org/10.1158/1535-7163.22485987
https://doi.org/10.1158/1535-7163.22485987
Supplementary Figure Legends from The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8458f8035ea491a889492af0bdae1f74
https://doi.org/10.1158/1535-7163.22485981.v1
https://doi.org/10.1158/1535-7163.22485981.v1
Autor:
Patrick Angibaud, Kristof van Emelen, Martin Page, Michel Janicot, Marc Du Jardin, Luc Andries, Ilse Goris, Willem Talloen, Kees Bol, Eugene Cox, Veronique Vreys, Ian Hickson, Ron Gilissen, Laurence Decrane, Bruno Roux, Isabelle Pilatte, Lut Janssen, Ann Belin, Wim Floren, Ann Marin, Peter King, Janine Arts
Supplementary Data from JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a60eef472554e462da36d628bd346f
https://doi.org/10.1158/1078-0432.22440625.v1
https://doi.org/10.1158/1078-0432.22440625.v1
Autor:
Lars-Eric Fielmich, Annemarie Buijs, Daniele Mori, Bas Viergever, Nihed Draoui, Anna Schepers, Mariana M. Costa e Silva, Mathijs Scholtus, Tokameh Mahmoudi, Tahlita Zuiverloon, Merel Derksen, Paul Gavine, Sylvia F. Boj, Richard Meijer, Onno Kranenburg, Janine Arts, Robert Vries
Publikováno v:
Cancer Research. 83:189-189
Conventional models for preclinical drug screening offer poor predictive value for patient response, causing high attrition rates of new agents in the clinic. HUB’s proprietary Patient-Derived Organoid (PDO) Technology enables long-term expansion o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd5683fc0e56775cb6a8a0358fa38a9b
https://doi.org/10.1158/1538-7445.am2023-189
https://doi.org/10.1158/1538-7445.am2023-189